VolitionRx Limited Operating Lease, Right-of-Use Asset, Amortization Expense
VolitionRx Limited (VNRX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $144.57 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $97.53K, a 48.09% increase year-over-year.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $47.04K, a 16.48% decline year-over-year.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $49.74K, a 11.92% decline year-over-year.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $60.77K, a 8.06% increase year-over-year.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for fiscal 2025 was $232.69K, a 3.08% increase from fiscal 2024.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for fiscal 2024 was $225.75K, a 13.42% decline from fiscal 2023.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for fiscal 2023 was $260.74K, a 2.71% increase from fiscal 2022.
- VolitionRx Limited operating lease, right-of-use asset, amortization expense for fiscal 2022 was $253.86K, a 27.06% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $97.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $144.57K 10-Q · filed 2026-08-13 | $194.31K derived: sum of 3 quarters · filed 2026-08-13 | $255.08K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $47.04K 10-Q · filed 2026-05-14 | $96.78K derived: sum of 2 quarters · filed 2026-05-14 | $157.56K derived: sum of 3 quarters · filed 2026-05-14 | $223.41K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $49.74K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $110.52K derived: sum of 2 quarters · filed 2026-03-31 | $176.37K derived: sum of 3 quarters · filed 2026-08-13 | $232.69K 10-K · filed 2026-03-31 |
| 2025-09-30 | $60.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $126.63K derived: sum of 2 quarters · filed 2026-08-13 | $182.95K 10-Q · filed 2025-11-13 | $239.43K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $65.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $122.18K 10-Q · filed 2026-08-13 | $178.66K derived: sum of 3 quarters · filed 2026-08-13 | $234.89K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $56.33K 10-Q · filed 2026-05-14 | $112.80K derived: sum of 2 quarters · filed 2026-05-14 | $169.04K derived: sum of 3 quarters · filed 2026-05-14 | $223.21K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $56.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $112.71K derived: sum of 2 quarters · filed 2026-03-31 | $166.88K derived: sum of 3 quarters · filed 2026-03-31 | $225.75K 10-K · filed 2026-03-31 |
| 2024-09-30 | $56.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $110.41K derived: sum of 2 quarters · filed 2025-11-13 | $169.27K 10-Q · filed 2025-11-13 | $235.98K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $54.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $113.03K 10-Q · filed 2025-08-14 | $179.74K derived: sum of 3 quarters · filed 2025-08-14 | $246.57K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $58.87K 10-Q · filed 2025-05-15 | $125.57K derived: sum of 2 quarters · filed 2025-05-15 | $192.40K derived: sum of 3 quarters · filed 2025-05-15 | $257.02K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $66.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $133.53K derived: sum of 2 quarters · filed 2025-03-31 | $198.16K derived: sum of 3 quarters · filed 2025-03-31 | $260.74K 10-K · filed 2025-03-31 |
| 2023-09-30 | $66.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $131.45K derived: sum of 2 quarters · filed 2024-11-14 | $194.04K 10-Q · filed 2024-11-14 | $254.46K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $64.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $127.21K 10-Q · filed 2024-08-14 | $187.63K derived: sum of 3 quarters · filed 2024-08-14 | $247.81K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $62.59K 10-Q · filed 2024-05-13 | $123.00K derived: sum of 2 quarters · filed 2024-05-13 | $183.19K derived: sum of 3 quarters · filed 2024-05-13 | $251.09K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $60.42K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $120.60K derived: sum of 2 quarters · filed 2024-03-25 | $188.50K derived: sum of 3 quarters · filed 2024-03-25 | $253.86K 10-K · filed 2024-03-25 |
| 2022-09-30 | $60.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $128.08K derived: sum of 2 quarters · filed 2023-11-14 | $193.44K 10-Q · filed 2023-11-14 | $245.16K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $67.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $133.26K 10-Q · filed 2023-08-14 | $184.98K derived: sum of 3 quarters · filed 2023-08-14 | $234.02K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $65.36K 10-Q · filed 2023-05-10 | $117.08K derived: sum of 2 quarters · filed 2023-05-10 | $166.12K derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | $51.72K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $100.76K derived: sum of 2 quarters · filed 2023-03-15 | $199.79K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $49.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $148.07K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $99.03K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |